恒瑞医药(01276.HK)：注射用SHR-A1904被药审中心纳入突破性治疗品种名单

Core Viewpoint - Heng Rui Medicine (01276.HK) announced that its injectable SHR-A1904 has been included in the list of breakthrough therapies by the National Medical Products Administration's Drug Evaluation Center [1] Group 1 - The company is recognized for its innovative approach with the inclusion of SHR-A1904 in the breakthrough therapy list [1] - This recognition may enhance the company's market position and potential for accelerated development and approval processes for SHR-A1904 [1]